$2.35
+0.12 (+5.38%)
Open$2.27
Previous Close$2.23
Day High$2.40
Day Low$2.24
52W High$7.13
52W Low$1.21
Volume—
Avg Volume345.7K
Market Cap154.69M
P/E Ratio—
EPS$-0.48
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+451.5% upside
Current
$2.35
$2.35
Target
$12.96
$12.96
$9.51
$12.96 avg
$17.52
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 42.71M | 37.98M | 43.70M |
| Net Income | -4,071,906 | -4,331,190 | -4,441,576 |
| Profit Margin | -9.5% | -11.4% | -10.2% |
| EBITDA | -6,278,520 | -5,337,134 | -5,924,921 |
| Free Cash Flow | -4,174,488 | -3,744,064 | -5,531,991 |
| Rev Growth | +12.9% | +2.3% | +21.5% |
| Debt/Equity | 0.88 | 1.10 | 1.06 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |